Guncar G, Pungercic G, Klemencic I, Turk V, Turk D
Department of Biochemistry and Molecular Biology, Jozcaronef Stefan Institute, Jamova 39, SLO-1000 Ljubljana, Slovenia.
EMBO J. 1999 Feb 15;18(4):793-803. doi: 10.1093/emboj/18.4.793.
The lysosomal cysteine proteases cathepsins S and L play crucial roles in the degradation of the invariant chain during maturation of MHC class II molecules and antigen processing. The p41 form of the invariant chain includes a fragment which specifically inhibits cathepsin L but not S. The crystal structure of the p41 fragment, a homologue of the thyroglobulin type-1 domains, has been determined at 2.0 A resolution in complex with cathepsin L. The structure of the p41 fragment demonstrates a novel fold, consisting of two subdomains, each stabilized by disulfide bridges. The first subdomain is an alpha-helix-beta-strand arrangement, whereas the second subdomain has a predominantly beta-strand arrangement. The wedge shape and three-loop arrangement of the p41 fragment bound to the active site cleft of cathepsin L are reminiscent of the inhibitory edge of cystatins, thus demonstrating the first example of convergent evolution observed in cysteine protease inhibitors. However, the different fold of the p41 fragment results in additional contacts with the top of the R-domain of the enzymes, which defines the specificity-determining S2 and S1' substrate-binding sites. This enables inhibitors based on the thyroglobulin type-1 domain fold, in contrast to the rather non-selective cystatins, to exhibit specificity for their target enzymes.
溶酶体半胱氨酸蛋白酶组织蛋白酶S和L在MHC II类分子成熟和抗原加工过程中恒定链的降解中起关键作用。恒定链的p41形式包含一个片段,该片段特异性抑制组织蛋白酶L而非S。已确定p41片段(甲状腺球蛋白1型结构域的同源物)与组织蛋白酶L复合物的晶体结构,分辨率为2.0 Å。p41片段的结构展示了一种新颖的折叠方式,由两个亚结构域组成,每个亚结构域都由二硫键稳定。第一个亚结构域是α螺旋-β链排列,而第二个亚结构域主要是β链排列。与组织蛋白酶L活性位点裂隙结合的p41片段的楔形形状和三环排列让人联想到半胱氨酸蛋白酶抑制剂的抑制边缘,从而证明了在半胱氨酸蛋白酶抑制剂中观察到的趋同进化的第一个例子。然而,p41片段不同的折叠方式导致与酶的R结构域顶部有额外的接触,这定义了决定特异性的S2和S1'底物结合位点。与相当非选择性的半胱氨酸蛋白酶抑制剂相比,这使得基于甲状腺球蛋白1型结构域折叠的抑制剂能够对其靶酶表现出特异性。